FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

Manufacturing Digital explores the top supply chains in the healthcare industry that ensure manufacturers can produce and ...

Biolinq received $100 million in a Series C funding round to bring its wearable for patients with diabetes to market, the ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Novo Nordisk shares fell Tuesday after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots. Shares fell as much as 9.8% in ...

Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...